How Surgeons Decide Which Parathyroid Glands to Remove

/in /by

Once a decision for surgery has been made and the surgeon has selected the desired imaging prior to the surgery, what actually takes place during the operation? How does the surgeon determine which gland or glands are abnormal?

The answers to these questions are not quite as straightforward or consistent among surgeons as one might expect. There are a variety of gland characteristics that a surgeon can rely on to decide which glands to remove. These characteristics include:

  1. The findings on preoperative imaging
  2. The shape, size, and color of the individual glands
  3. Comparison of the four glands during the surgery
  4. Measurement of PTH drop following removal of one or more glands
  5. Pathologic assessment of the gland, either by frozen section (available during the surgery, but adds time) or permanent section (only available a few days after)

In practice, these five inputs tend to sort surgeons into two broad philosophies.

Philosophy 1: Trust the imaging, find the one gland

Some surgeons rely heavily on preoperative imaging to decide if they can select a single gland to locate and remove. These surgeons typically will not recommend surgery unless at least one, and preferably two, preoperative imaging tests point to a single gland as the culprit. Given this selectivity, the operation is focused on finding only one gland presumed to be abnormal.

Once it’s identified, the surgeon typically uses intraoperative PTH measurement to see if the level has dropped. If it hasn’t dropped enough, the operation is extended to look for the other glands, with PTH rechecked after any additional glands are removed until the level falls sufficiently.

Some surgeons in this camp also send every removed gland for frozen section to confirm it’s parathyroid tissue and to get the pathologist’s estimate of “hypercellularity.” That said, there’s no real consensus on whether hypercellularity correlates with PTH overproduction, so it’s debatable how useful that feedback actually is, and sometimes the pathologist can’t even confirm the tissue is parathyroid gland from the frozen section alone.

The tradeoff: if the preoperative imaging is accurate and the PTH level drops sufficiently, this can be the least invasive approach. But imaging can localize one abnormal gland while missing a second one that doesn’t show up and the PTH value might still drop enough to look like a cure even though an abnormal gland remains. Those patients sometimes aren’t discovered to have persistent hyperparathyroidism until lab work at six months shows the calcium is still high. And if the PTH doesn’t drop after the single gland comes out, relying on intraoperative measurements can significantly prolong the surgery, since each result takes about 20–30 minutes to come back.

There’s also a judgment call baked into this approach: what PTH level counts as evidence of cure? Historically, surgeons have accepted a level that’s 50% or less of the preoperative value but that criterion can be misleading, especially when the starting PTH was very high.

Philosophy 2: Find all four glands, every time

Other surgeons choose to identify all four glands at the initial operation regardless of what the preoperative imaging showed. The imaging becomes a roadmap rather than a limit; the surgeon incorporates it with what’s actually seen at surgery. The glands flagged by sestamibi scan, ultrasound, or other imaging are expected to appear abnormal and are removed; the remaining glands are exposed to confirm they look normal, or “dormant.”

Some patients have what’s called four-gland hyperplasia, where all four glands are contributing to the hyperparathyroidism to varying degrees. In these patients, all four glands may look similar,  each with some abnormality, but not necessarily large. Here the surgeon must identify the most normal-appearing gland, leave a portion of it in place, and remove the other three completely.

Intraoperative PTH measurement isn’t routinely needed with this approach, since it’s a safe assumption that identifying and removing the abnormal gland(s) from all four will cure the patient. PTH is simply checked later, in recovery or at a follow-up visit.

The tradeoff: this approach doesn’t depend on positive preoperative imaging and skips the extra operating-room time for intraoperative PTH. But it’s more invasive, since dissection extends to all four glands, which raises the incidence of temporary hypocalcemia (and, rarely, prolonged or permanent hypocalcemia if the “normal” glands’ blood supply is compromised during dissection). More extensive dissection also means a higher chance of temporary hoarseness after surgery, though this is almost always transient.

Neither approach is simply right

Both philosophies are defensible, and the best surgeons choose deliberately based on the quality of their imaging, their patient population, and how much operative time they’re willing to spend chasing a PTH number. But deciding on a philosophy is only the first challenge. Once you’re actually in the neck, you still have to answer a much more concrete question: what does an abnormal gland actually look like? That’s the subject of the next post in this series.

How Surgeons Identify an Abnormal Parathyroid Gland—Part 2 of a Series “Imaging Guides, Experience Decides”

/in /by

Once the diagnosis of primary hyperparathyroidism has been established from the calcium and PTH levels, and a decision for surgery is made, the next step is usually to determine what additional information should be obtained in order to assure a successful operation.

This is where imaging becomes useful.

It is worth repeating the central point from Part One: imaging does not make the diagnosis. Imaging is performed after the diagnosis has been made to help the surgeon decide where the abnormal gland is likely to be and how best to approach the operation. Even patients with negative imaging remain candidates for surgery if the biochemical diagnosis is clear.

There are several different imaging studies available, and they do not all provide the same information.

1. The sestamibi scan

The sestamibi scan has been one of the most commonly used parathyroid localization studies for many years.

A small amount of radioactive material is injected into the bloodstream. Hyperfunctioning parathyroid tissue often takes up and retains more of the sestamibi than the surrounding tissues. Images are then obtained to look for an area of increased activity.

When the scan shows one convincing focus, it provides useful evidence that a particular gland is hyperfunctioning.

But there are limitations.

A positive sestamibi scan does not prove that the other three glands are normal. It simply tells us that one gland accumulated enough tracer to be seen.

And a negative sestamibi scan does not mean that the patient does not have hyperparathyroidism. It means only that the scan did not localize the abnormal gland. Sestamibi is also less reliable when more than one gland is abnormal.

This distinction is extremely important because I have seen patients whose diagnosis was questioned simply because their sestamibi scan was negative. If the calcium and PTH establish primary hyperparathyroidism, a negative scan does not undo that diagnosis.

If the sestamibi scan is performed immediately before surgery, there can be an additional benefit. The injected sestamibi is still present in the tissues during the operation, allowing the surgeon to use a handheld gamma probe to measure radioactivity. Hyperfunctioning parathyroid tissue usually retains more sestamibi than surrounding tissues, which can help locate an abnormal gland. Once tissue is removed, its radioactivity can also be measured immediately and can provide another clue that the specimen is parathyroid tissue, without waiting for a frozen-section pathology report. I will discuss this technique in more detail later in this series.

2. Ultrasound of the neck

Ultrasound looks at the problem differently.

Rather than measuring the uptake of a radioactive tracer, ultrasound looks directly at the anatomy of the neck. An enlarged parathyroid gland often has a characteristic appearance and may be seen behind or adjacent to the thyroid gland. Normal or dormant glands are rarely seen on ultrasound because they blend in with the other surrounding soft tissues.

Ultrasound has several advantages. There is no radiation, it is relatively inexpensive, and it also gives us useful information about the thyroid gland.

One limitation is that ultrasound is very dependent on the person performing and interpreting the study. It can also have difficulty identifying glands that are very deep, behind the trachea or esophagus, or located somewhere unusual.

When an ultrasound and sestamibi scan both identify the same gland, that gives us considerably more confidence about where the problem is located. These studies are often complementary rather than competing tests.

3. 4D CT scanning

A 4D CT scan provides much more detailed anatomical information.

The term “4D” refers to the fact that the scan looks not only at the three-dimensional anatomy but also at how a suspected parathyroid gland takes up and releases intravenous contrast over time.

This characteristic enhancement pattern can help distinguish abnormal parathyroid tissue from lymph nodes, thyroid tissue, and other structures in the neck.

4D CT can be particularly useful when the ultrasound or sestamibi scan is negative or when the studies disagree. It can also be very helpful for glands in unusual locations. Studies have shown that 4D CT can localize glands that were not seen on traditional imaging.

The tradeoff is greater radiation exposure and the need for intravenous contrast, so it is not necessarily the first test every patient needs.

4. Choline PET imaging

A newer option is fluorocholine PET/CT. Parathyroid tissue has a high rate of cellular membrane activity and can preferentially accumulate radiolabeled choline. This can allow PET imaging to identify very small or difficult-to-localize abnormal glands.

Choline PET it is gradually assuming a greater role when more traditional studies are negative or equivocal, most often in patients who have already had an unsuccessful first operation. Published studies have reported very high localization sensitivity in selected patients. Availability and insurance coverage can be limiting, so it is not currently a routine study for most patients.

5. No imaging test is perfect

This may be the most important point in Part Two.

Every imaging study provides evidence about which gland or glands might be abnormal. None provides absolute proof.

If a sestamibi scan, ultrasound, and 4D CT all point to the same gland, we can be very confident that gland is abnormal. But that still does not prove that the other glands are functioning normally.

Conversely, if every scan is negative, that does not mean there is no abnormal gland.

If the biochemical diagnosis is correct, there is abnormal parathyroid function somewhere.

That is why I think of imaging as creating a road map for the surgeon. Sometimes the map is excellent. Sometimes it is incomplete. And occasionally it points us in the wrong direction.

Ultimately, the surgeon must combine what was learned before the operation with what is found during the operation.

That leads directly to Part Three.

Once the neck is explored, what does an abnormal parathyroid gland actually look like? Is a larger gland always the abnormal one? What does a normal gland look like? And perhaps most interestingly, what happens to the other parathyroid glands when one gland has been overproducing PTH for a long time?

In Part Three, I will discuss the visual appearance of normal, hyperfunctioning, and suppressed—or what I often call “dormant”—parathyroid glands and how those findings help guide surgical decision-making.

Disclaimer

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s history, laboratory findings, imaging, operative findings, and overall clinical situation.

How Surgeons Identify an Abnormal Parathyroid Gland

/in /by

It is extremely important to understand that we do not need imaging to make a diagnosis of primary hyperparathyroidism. The diagnosis is based on the laboratory findings.

Sometimes those findings are very clear, and sometimes they fall into a gray zone.

If the calcium is repeatedly high and the parathyroid hormone level is elevated—or even “normal” when it should be suppressed—primary hyperparathyroidism is usually the explanation. If the calcium is high and the PTH is appropriately suppressed, then the explanation for the high calcium lies elsewhere.

Borderline situations do occur. If the calcium is only high-normal, or the PTH is only modestly elevated, additional laboratory evaluation may be necessary before the diagnosis is certain. There are also uncommon conditions that can mimic primary hyperparathyroidism, so the lab results always need to be interpreted in the context of the whole patient.

This series addresses the situation in which the diagnosis has already been confirmed.

I have written other posts about when surgery should be recommended, but in most cases surgery should at least be considered once the diagnosis is certain based on the lab work. Some physicians still reserve the decision about surgery until after imaging is performed. That is not the ideal way to think about it.

Once the diagnosis is confirmed biochemically, there is abnormal parathyroid function somewhere. The remaining question is which gland—or glands—is responsible.

That distinction is important because imaging does not tell us whether the patient has hyperparathyroidism. It helps us localize the abnormal gland or glands after the diagnosis has already been made.

In this series, I will look at the different ways we try to identify the abnormal gland or glands, including:

  • sestamibi scanning
  • ultrasound of the neck
  • 4D CT scanning
  • choline PET imaging
  • intraoperative use of the unique autofluorescence characteristics of parathyroid tissue
  • visual assessment of the glands during surgery
  • pathology findings
  • intraoperative functional testing

Each of these provides useful information, but none of them tells the whole story by itself.

Parathyroid surgery came before modern imaging

Surgery for hyperparathyroidism has a long history. The first generally recognized successful parathyroidectomy for primary hyperparathyroidism was performed by Felix Mandl in Vienna in 1925.

At that time, surgeons had none of the imaging studies we use today. They also could not measure intact PTH levels.

They relied heavily on the clinical picture, serum and urinary calcium measurements, skeletal findings, and exclusion of other causes of hypercalcemia.

Without a PTH level, it was much more important to consider all of the other possible explanations for high calcium before proceeding to surgery. That kind of exhaustive work-up is much less commonly necessary today because modern intact PTH testing allows us to determine whether the parathyroid glands are responding appropriately to the calcium level.

Once the surgeon was confident in the diagnosis, the traditional operation was a bilateral neck exploration. The surgeon would identify all four parathyroid glands and visually decide which gland—or glands—appeared abnormal.

Surgeons relied heavily on the size, color, shape, and appearance of the glands, often supplemented by pathology to confirm that tissue removed was parathyroid tissue.

Large cervical incisions were already routine for thyroid surgery, which made up much of neck surgery at the time, so parathyroid operations were generally performed through a similar exposure.

Fortunately, much of that is now history.

Modern localization studies have allowed surgeons to plan much more focused operations in many patients. But they have also created a new source of confusion: patients and even physicians sometimes begin to think that the scan makes the diagnosis.

It does not.

The lab work makes the diagnosis. The imaging helps us decide where to look.

In Part Two, I will review the preoperative imaging studies available today and explain what each one can—and cannot—tell us about which parathyroid gland is abnormal. Not all surgeons use these studies in the same way, and a positive or negative scan does not always mean what patients assume it means.

Disclaimer

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s history, laboratory findings, imaging, operative findings, and overall clinical situation.

Is There a “Wait and See” Role in Hyperparathyroidism?

/in , /by

u

In most patients with primary hyperparathyroidism, surgery is the treatment that should be considered first. It is the only treatment that actually cures the problem. Once the diagnosis is clear, the main question is usually not whether anything should be done, but whether there is a good reason not to proceed with surgery right away.

Primary hyperparathyroidism is a biochemical diagnosis. If the calcium is high and the parathyroid hormone level is also high, or “inappropriately normal” when it should be suppressed, that establishes the diagnosis. At that point, the dsually turns to management.

The reason surgery is the default option is straightforward. Primary hyperparathyroidism is not just a lab abnormality. It can affect energy level, concentration, bones, kidneys, and overall quality of life. Some patients already have kidney stones, reduced bone density, or other measurable effects of the disease. Others do not have dramatic findings, but they still feel tired, foggy, weak, achy, or just not quite right. In either situation, surgery is the one treatment that can actually correct the underlying problem. In the hands of an experienced parathyroid surgeon, surgery can usually be done as an outpatient procedure, with a high likelihood of success and a very low risk of complications.

This is also why it is important not to minimize the diagnosis just because the calcium is “only a little high.” Mild hypercalcemia can still reflect a real parathyroid problem. In many patients, the diagnosis and the recommendation for surgery are already clear from the lab work and the overall clinical picture.

That said, there can be a wait-and-see role in selected patients. But think of it as a qualified exception, not the starting point. A patient might be a reasonable candidate for observation if the calcium elevation is mild, kidney function is preserved, there is no history of kidney stones, bone density is normal or near normal, and the patient is not having significant symptoms that seem attributable to the disease. Even then, observation is not the same as doing nothing. There should be a deliberate plan for follow-up.

That follow-up usually includes repeat calcium testing, monitoring kidney function, and periodic bone density evaluation. The purpose is to watch for evidence that the disease is progressing or beginning to affect the kidneys or bones. If that happens, the argument for surgery becomes stronger.

So is there a “wait and see” role in hyperparathyroidism? Yes, for some patients. But in most cases, the more appropriate way to think about it is that surgery is the primary treatment, and observation is an option that may be reasonable only when the overall picture is favorable and careful follow-up is in place.

Disclaimer

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s history, laboratory findings, symptoms, kidney function, bone health, and overall clinical situation.

What Tests Do I Really Need Before I Decide on Parathyroid Surgery?

/in , /by

Patients often ask this question after they learn their calcium is high. That is the right question. The answer is that the decision almost always starts with the lab work, but it should also include the patient’s symptoms and any signs that the disease may already be affecting the kidneys, bones, or other organs. Primary hyperparathyroidism is fundamentally a biochemical diagnosis. Imaging and additional studies can be helpful, but they do not make the diagnosis.

1. The most important tests are the calcium and PTH levels.
In most cases, the key decision point comes from the blood work. If the calcium is high and the parathyroid hormone level is also high, or “inappropriately normal” when it should be suppressed, that is the central evidence for primary hyperparathyroidism. In many patients, those labs already make the diagnosis clear enough that surgery can be discussed seriously right away. The scan does not make that decision. The blood work does. You will note that ultrasounds and Sestamibi scans are not even mentioned in this article. These scans really are only utilized in planning an operation and need not be done prior to that.

2. Symptoms matter, even when they are subjective.
Not every patient presents with kidney stones or obvious osteoporosis. Many patients come in because they feel tired, foggy, run down, achy, anxious, or just not quite themselves. These symptoms are not always easy to measure, but they are still part of the decision-making. They often fit with what we see in patients with hyperparathyroidism. When the lab findings are convincing and the patient is having symptoms that may reasonably be related to high calcium, that often strengthens the case for surgery even if no other test has yet been done. Current guidelines note that neurocognitive and quality-of-life symptoms are recognized clinically, even though they are not always used as strict formal criteria the same way kidney or bone findings are.

3. Additional testing can show whether the disease is already affecting the body.
Once the diagnosis looks likely, the next question is whether the hyperparathyroidism may already be causing systemic problems. That is where tests such as kidney function, kidney imaging, 24-hour urine calcium, and bone density can become useful. A history of kidney stones, silent stones seen on imaging, reduced kidney function, or bone loss on DEXA all strengthen the argument that the disease is not just a lab abnormality. These findings are well-established reasons to recommend surgery.

4. In most patients, these extra tests do not determine whether surgery is needed. They help show how far the disease has progressed.
This is an important practical point. In many patients, the calcium and PTH pattern is already convincing enough, and the overall picture already supports surgery without waiting for a 24-hour urine calcium or a bone density test. Those tests are still worthwhile because they can document whether there has already been progression to kidney or bone involvement. But in most straightforward cases, they do not change the overall recommendation for surgery. They add information, more than changing the basic conclusion.

5. Borderline cases are where the extra testing can matter most.
When the labs are only mildly abnormal, the additional studies can help move the decision one way or the other. For example, a patient with only modest calcium elevation but a history of kidney stones and high urinary calcium may look very different once that full picture is known. Likewise, a patient with borderline lab findings who already shows osteopenia or osteoporosis on DEXA may have a stronger reason to move toward surgery sooner rather than later. Current guidance includes renal stones, hypercalciuria, osteoporosis, vertebral fracture, and reduced kidney function among the findings that can support operative management.

Closing paragraph
So what tests do you really need before deciding on parathyroid surgery? First, you need the right lab evaluation to establish whether the high calcium is truly coming from a parathyroid problem. After that, the decision is supported by the patient’s symptoms and by whether there is evidence that the disease is already affecting the kidneys or bones. In many cases, the diagnosis and the recommendation for surgery are already fairly clear from the labs and the overall clinical picture. Additional testing is often helpful, but it is most valuable for showing the impact of the disease and for clarifying borderline situations.

Disclaimer
This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s history, laboratory findings, symptoms, imaging, and overall clinical situation.

Five Things to Know About Intraoperative PTH Monitoring

/in /by

1. Intraoperative PTH monitoring is a tool, not the whole operation.
Patients may hear a lot about intraoperative PTH monitoring and assume it is the main thing that makes parathyroid surgery successful. It is better thought of as one useful tool. The real goal of surgery is to identify and remove the overactive parathyroid gland or glands safely and effectively. Intraoperative PTH monitoring can help confirm that the right tissue has been removed, but it does not replace sound judgment and experience.

2. Some surgeons use it routinely, and some use it selectively.
This is one reason patients see so many different opinions online. Some surgeons check intraoperative PTH in nearly every case. Others use it in selected patients, such as when imaging is not clear, when more than one gland may be abnormal, or when the findings in the operating room are not straightforward. A surgeon’s approach often reflects training, experience, and how they structure their operation.

3. One advantage is that it gives real-time feedback.
Parathyroid hormone levels usually fall within 10-15 minutes after the overactive gland is removed. That means the surgeon can often get biochemical confirmation during the operation that the hyperparathyroidism has been corrected. This can be reassuring, especially in a focused operation where the surgeon is not planning to explore the entire neck.  It does take time to get the result back from the lab, typically 20-30 minutes after each blood sample is drawn. 

4. It also has limits.
Intraoperative PTH monitoring is not perfect. It adds steps to the procedure, will increase the time in the operating room, and sometimes the results are not completely straightforward. A falling PTH is helpful, but it still has to be interpreted in the context of the patient’s lab values, imaging, anatomy, and operative findings. It is an aid, not a guarantee. 

5. The important question is not simply whether it is used, but why.
Patients often ask whether intraoperative PTH monitoring is “the best way.” A better question is whether the surgeon has a clear plan and can explain why this tool is or is not being used in that particular case. Good parathyroid surgery is not defined by one single technique. It is defined by accurate diagnosis, thoughtful planning, careful surgery, and a high likelihood of cure.

Closing paragraph:
If you are talking with a surgeon about parathyroid surgery, it is reasonable to ask whether intraoperative PTH monitoring will be used and how it fits into the plan. The answer should make sense in the context of your case. Different surgeons may use different methods, but the goal is always the same: to treat the hyperparathyroidism safely and effectively.

Disclaimer:
This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s full history, laboratory findings, imaging, and overall clinical situation.

How Do You Know If High Calcium Is Coming From a Parathyroid Problem?

/in , /by

When a blood test shows a high calcium level, one of the first questions is what is causing it. In many cases, the answer is a parathyroid problem, specifically primary hyperparathyroidism. But not every case of high calcium comes from the parathyroid glands, so the lab results have to be interpreted carefully.

The key test is the parathyroid hormone level, usually called the PTH.

If your calcium is high, your parathyroid glands should normally respond by making very little PTH. In other words, a high calcium level should suppress the parathyroid glands. So if the calcium is elevated and the PTH is also elevated, that strongly supports a diagnosis of primary hyperparathyroidism.

In fact, the diagnosis can also be made when the PTH is technically in the normal range. That may sound confusing, but it is actually very important. If the calcium is high, then a “normal” PTH is not really normal. It is inappropriately normal, because it should be low. A non-suppressed PTH in the setting of high calcium points to a parathyroid source.

On the other hand, if the calcium is high and the PTH is clearly low, that usually means the parathyroid glands are behaving normally. They are being turned off, just as they should be. In that situation, the high calcium is probably coming from some other cause, and the evaluation should move in a different direction.

This is why the combination of the two numbers matters more than either one alone. A calcium level by itself does not tell the whole story. A PTH level by itself does not either. The answer comes from looking at them together.

Other tests may also be helpful. Depending on the situation, the workup may include vitamin D measurement, kidney function, urine calcium testing, and sometimes bone density evaluation. These tests help confirm the diagnosis and show whether the condition may already be affecting bones or kidneys.

It is also important to understand what imaging can and cannot do. A sestamibi scan, ultrasound, or CT scan does not make the diagnosis of hyperparathyroidism. The diagnosis is made from the laboratory findings. Imaging is used later, mainly to help plan surgery if surgery is being considered.

The bottom line is this: if your calcium is high, the way to tell whether it is coming from a parathyroid problem is to check the PTH and interpret the two results together. If the calcium is high and the PTH is not suppressed, primary hyperparathyroidism is usually the reason.

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s full history, laboratory findings, and overall clinical situation.

High Calcium on a Routine Blood Test: What Should Happen Next?

/in , /by

Many people are surprised when a routine blood test shows a high calcium level. They may feel fine, or they may have symptoms they never connected to calcium at all. Either way, it is not something to ignore. Persistent hypercalcemia deserves a careful evaluation, and one of the most common causes is primary hyperparathyroidism.

A single mildly high calcium level does not always mean there is a serious problem. Lab error, dehydration, medications, and other conditions can sometimes play a role. But if the calcium stays elevated on repeat testing, the next step is usually to look at the parathyroid hormone (PTH) level at the same time. If the PTH is also high, or “inappropriately normal” when it should be suppressed, then with just that information a diagnosis of primary hyperparathyroidism is established. If your parathyroid glands are all functioning normally, then they will not be producing much PTH at all if your calcium is high. There is no other explanation for a non-suppressed PTH with a high calcium other than a diagnosis of primary hyperparathyroidism. If you have a high calcium and a low PTH, that means your parathyroid glands are responding appropriately. In this situation other explanations for high calcium should be considered.

Age does matter though. In younger adults, especially patients in their twenties, normal calcium levels may run a little higher. By contrast, in patients who are middle-aged or older, a calcium level that is consistently above about 10 mg/dL deserves closer attention. Calcium reference ranges vary by laboratory, but normal upper limits tend to be higher in younger people and decline with age.

If repeat testing confirms hyperparathyroidism, the workup may include kidney function, vitamin D measurement, and sometimes urine calcium testing or bone density evaluation. The goal is not just to explain the lab value, but to understand whether the condition may already be affecting bones, kidneys, energy level, or quality of life.

The important point is simple: if your calcium is repeatedly high, do not just file that result away. It is worth finding out why. In many cases, the answer is treatable.

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s full history, laboratory findings, and overall clinical situation.

Is There a “Magic Number” for High Calcium?

/in /by

One of the most common misunderstandings about high calcium is the idea that a slightly elevated calcium level means a patient has only a mild problem.

That is not a reliable way to think about primary hyperparathyroidism.

But first let’s clarify that we are talking about someone who has a PTH level that is inappropriately high for a given calcium level. This is what establishes a diagnosis of hyperparathyroidism. Many patients are told to simply “watch it for a while” when calcium is only modestly elevated on routine blood work. In some situations, careful follow-up may be part of the discussion. But a mildly elevated calcium level should not automatically be dismissed as unimportant.

When primary hyperparathyroidism is present, the calcium number by itself does not tell the whole story.

There Is No Single “Magic Number”

A common myth is that patients only need to worry when calcium rises above a certain number.

There is no single calcium level that defines how serious a patient’s hyperparathyroidism is. Calcium levels and parathyroid hormone levels can fluctuate. Some patients with proven parathyroid disease never have dramatically elevated calcium levels.

That matters because patients sometimes assume that if the number is not very high, the condition must not be significant. That is not always true.

Why “Mild” High Calcium Can Still Matter

Primary hyperparathyroidism should be evaluated based on the overall clinical picture, not just one lab value.

The evaluation and treatment decision depend on more than the highest calcium level. They depend on the pattern over time, the parathyroid hormone level, bone health, kidney stone history, symptoms, age, and other individual factors.

In other words, a lower calcium level does not necessarily mean a trivial problem.

What If You Do Not Notice Symptoms?

This is another area where patients can be misled.

Some people with hyperparathyroidism have obvious symptoms such as fatigue, poor sleep, body aches, bone pain, poor concentration, headaches, or depression. Others feel relatively well, or they attribute their symptoms to aging, stress, or another condition.

Some patients considered “asymptomatic” may actually have subtler symptoms that are easy to overlook.

That is one reason the absence of dramatic symptoms does not automatically rule out a meaningful problem.

Why Proper Evaluation Matters

The real concern is not whether a calcium level crosses some arbitrary line. The more important issue is whether a patient with persistent high calcium is being evaluated appropriately.

Over time, untreated primary hyperparathyroidism may contribute to problems such as:

  • osteoporosis
  • kidney stones
  • declining kidney function
  • hypertension
  • other long-term health effects

That does not mean every patient with a mildly elevated calcium level needs immediate surgery. It does mean the finding deserves thoughtful attention rather than casual dismissal.

The Bottom Line

If your calcium is high, the most important question is not whether it has reached a “magic number.”

The more important question is whether the finding could represent primary hyperparathyroidism and whether it has been evaluated carefully.

A calcium level that is only slightly elevated can still matter. The right next step is not to focus on one number alone, but to look at the whole picture.

This article is for general education only and is not personal medical advice. Individual recommendations depend on a patient’s full history, laboratory findings, and overall clinical situation.

What’s All the Hype About Vitamin K2?

/in /by

Vitamin K2 has been getting more attention lately in relation to hyperparathyroidism, calcium, and vitamin D supplements, especially in conversations about bone health and calcium metabolism. Interestingly, despite a growing amount of information available online, vitamin K2 still lives mostly in the background when it comes to mainstream, peer-reviewed medical literature.

There are a few reasons for that. One is practical: vitamin K2 is not patentable in any meaningful way, which means there is very little financial incentive for large pharmaceutical companies to fund expensive clinical trials. As a result, you won’t see vitamin K2 featured prominently in the major journals the way you might see a new drug or device.

Another issue is that we don’t have a clearly established recommended daily allowance (RDA) for vitamin K2. Different populations consume very different amounts through diet, and the research hasn’t yet settled on a single “correct” dose. Complicating matters further, there is no widely available, reliable blood test to measure vitamin K2 levels. That makes large-scale studies harder to design and interpret.

It’s also important to clarify a common point of confusion: vitamin K2 is not the same as vitamin K1. Vitamin K1 is primarily involved in blood clotting and is what most people think of when they hear “vitamin K.” Vitamin K2, on the other hand, plays a different role—helping direct calcium to where it belongs, particularly into bones and away from soft tissues. Because they share a name, the two are often lumped together, but functionally they are quite distinct.

In my own practice, I have been recommending the addition of vitamin K2 alongside calcium and vitamin D for many years, particularly in patients concerned about bone health and calcium balance. Only more recently have other parathyroid experts begun to publicly emphasize the same approach.

Based on the available evidence and clinical experience, my personal recommendation for vitamin K2 (MK-7) supplementation is 200–300 micrograms daily. While this is not an official guideline, it reflects what I believe to be a reasonable and safe range for most adults.

As with many nutritional supplements, vitamin K2 sits at the intersection of emerging science and clinical judgment. The absence of large trials does not mean it lacks value—it often means the system has little incentive to study it.

This information is educational and not a substitute for medical advice. Talk with your own clinician about your specific situation before starting any new supplement.